Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 520 entries
Sorted by: Best Match Show Resources per page
CORRIGENDUM: Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease.

Clinical pharmacology and therapeutics

[No authors listed]
PMID: 28547828
Clin Pharmacol Ther. 2009 Dec;86(6):683. doi: 10.1038/clpt.2009.180.

No abstract available.

Cite
CORRIGENDUM: Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease. Clin Pharmacol Ther. 2009;86(6):683doi: 10.1038/clpt.2009.180.
(2009). CORRIGENDUM: Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease. Clinical pharmacology and therapeutics, 86(6), 683. https://doi.org/10.1038/clpt.2009.180
"CORRIGENDUM: Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease." Clinical pharmacology and therapeutics vol. 86,6 (2009): 683. doi: https://doi.org/10.1038/clpt.2009.180
CORRIGENDUM: Effects of Selective Serotonin Reuptake Inhibitor Therapy on Endothelial Function and Inflammatory Markers in Patients With Coronary Heart Disease. Clin Pharmacol Ther. 2009 Dec;86(6):683. doi: 10.1038/clpt.2009.180. PMID: 28547828.
Copy Download .nbib Format: NLM
Relations between the American Medical Association, the American Therapeutic Society, and the American Society for Clinical Pharmacology and Therapeutics.

Clinical pharmacology and therapeutics

Grenfell RF.
PMID: 29023651
Clin Pharmacol Ther. 1990 Feb;47:280-281. doi: 10.1002/cpt.1990.47.s2.280.

No abstract available.

Cite
Grenfell RF. Relations between the American Medical Association, the American Therapeutic Society, and the American Society for Clinical Pharmacology and Therapeutics. Clin Pharmacol Ther. 1990;47:280-281doi: 10.1002/cpt.1990.47.s2.280.
Grenfell, R. F. (1990). Relations between the American Medical Association, the American Therapeutic Society, and the American Society for Clinical Pharmacology and Therapeutics. Clinical pharmacology and therapeutics, 47280-281. https://doi.org/10.1002/cpt.1990.47.s2.280
Grenfell, Raymond F. "Relations between the American Medical Association, the American Therapeutic Society, and the American Society for Clinical Pharmacology and Therapeutics." Clinical pharmacology and therapeutics vol. 47 (1990): 280-281. doi: https://doi.org/10.1002/cpt.1990.47.s2.280
Grenfell RF. Relations between the American Medical Association, the American Therapeutic Society, and the American Society for Clinical Pharmacology and Therapeutics. Clin Pharmacol Ther. 1990 Feb;47:280-281. doi: 10.1002/cpt.1990.47.s2.280. PMID: 29023651.
Copy Download .nbib Format: NLM
The American Society for Clinical Pharmacology and Therapeutics: Programs to support education in clinical pharmacology.

Clinical pharmacology and therapeutics

Nierenberg DW, Atkinson AJ, Brater DC, Drayer I.
PMID: 29023654
Clin Pharmacol Ther. 1990 Feb;47:262-269. doi: 10.1002/cpt.1990.47.s2.262.

No abstract available.

Cite
Nierenberg DW, Atkinson AJ, Brater DC, et al. The American Society for Clinical Pharmacology and Therapeutics: Programs to support education in clinical pharmacology. Clin Pharmacol Ther. 1990;47:262-269doi: 10.1002/cpt.1990.47.s2.262.
Nierenberg, D. W., Atkinson, A. J., Brater, D. C., & Drayer, I. (1990). The American Society for Clinical Pharmacology and Therapeutics: Programs to support education in clinical pharmacology. Clinical pharmacology and therapeutics, 47262-269. https://doi.org/10.1002/cpt.1990.47.s2.262
Nierenberg, David W, et al. "The American Society for Clinical Pharmacology and Therapeutics: Programs to support education in clinical pharmacology." Clinical pharmacology and therapeutics vol. 47 (1990): 262-269. doi: https://doi.org/10.1002/cpt.1990.47.s2.262
Nierenberg DW, Atkinson AJ, Brater DC, Drayer I. The American Society for Clinical Pharmacology and Therapeutics: Programs to support education in clinical pharmacology. Clin Pharmacol Ther. 1990 Feb;47:262-269. doi: 10.1002/cpt.1990.47.s2.262. PMID: 29023654.
Copy Download .nbib Format: NLM
The responsibility for the study protocol in a drug trial.

International journal of clinical pharmacology, therapy, and toxicology

Schmidt R.
PMID: 3997301
Int J Clin Pharmacol Ther Toxicol. 1985 Mar;23(3):158-60.

A well-designed protocol is an essential part of any clinical trial. In a drug trial it should be the result of a joint effort involving the physician performing the trial at the clinic and the specialist in the drug...

Cite
Schmidt R. The responsibility for the study protocol in a drug trial. Int J Clin Pharmacol Ther Toxicol. 1985;23(3):158-60
Schmidt, R. (1985). The responsibility for the study protocol in a drug trial. International journal of clinical pharmacology, therapy, and toxicology, 23(3), 158-60.
Schmidt, R. "The responsibility for the study protocol in a drug trial." International journal of clinical pharmacology, therapy, and toxicology vol. 23,3 (1985): 158-60.
Schmidt R. The responsibility for the study protocol in a drug trial. Int J Clin Pharmacol Ther Toxicol. 1985 Mar;23(3):158-60. PMID: 3997301.
Copy Download .nbib Format: NLM
Poor drug therapy.

Clinical pharmacology and therapeutics

FRIEND DG.
PMID: 13895326
Clin Pharmacol Ther. 1962 Jul-Aug;3:557-60. doi: 10.1002/cpt196234557.

No abstract available.

Cite
FRIEND DG. Poor drug therapy. Clin Pharmacol Ther. 1962;3:557-60doi: 10.1002/cpt196234557.
FRIEND, D. G. (1962). Poor drug therapy. Clinical pharmacology and therapeutics, 3557-60. https://doi.org/10.1002/cpt196234557
FRIEND, D G. "Poor drug therapy." Clinical pharmacology and therapeutics vol. 3 (1962): 557-60. doi: https://doi.org/10.1002/cpt196234557
FRIEND DG. Poor drug therapy. Clin Pharmacol Ther. 1962 Jul-Aug;3:557-60. doi: 10.1002/cpt196234557. PMID: 13895326.
Copy Download .nbib Format: NLM
Necessity and requirements of bridging studies and their present status in Japan.

International journal of clinical pharmacology and therapeutics

Naito C.
PMID: 10706195
Int J Clin Pharmacol Ther. 2000 Feb;38(2):80-6. doi: 10.5414/cpp38080.

The mainstays of the harmonized final document about ethnic factors in the acceptability of foreign clinical data include a complete clinical data package and a bridging study (for efficacy and/or for safety). A clinical data package that meets all...

Cite
Naito C. Necessity and requirements of bridging studies and their present status in Japan. Int J Clin Pharmacol Ther. 2000;38(2):80-6doi: 10.5414/cpp38080.
Naito, C. (2000). Necessity and requirements of bridging studies and their present status in Japan. International journal of clinical pharmacology and therapeutics, 38(2), 80-6. https://doi.org/10.5414/cpp38080
Naito, C. "Necessity and requirements of bridging studies and their present status in Japan." International journal of clinical pharmacology and therapeutics vol. 38,2 (2000): 80-6. doi: https://doi.org/10.5414/cpp38080
Naito C. Necessity and requirements of bridging studies and their present status in Japan. Int J Clin Pharmacol Ther. 2000 Feb;38(2):80-6. doi: 10.5414/cpp38080. PMID: 10706195.
Copy Download .nbib Format: NLM
The use and misuse of statistics in medical publications.

Clinical pharmacology and therapeutics

MAINLAND D.
PMID: 14420026
Clin Pharmacol Ther. 1960 Jul-Aug;1:411-22.

No abstract available.

Cite
MAINLAND D. The use and misuse of statistics in medical publications. Clin Pharmacol Ther. 1960;1:411-22
MAINLAND, D. (1960). The use and misuse of statistics in medical publications. Clinical pharmacology and therapeutics, 1411-22.
MAINLAND, D. "The use and misuse of statistics in medical publications." Clinical pharmacology and therapeutics vol. 1 (1960): 411-22.
MAINLAND D. The use and misuse of statistics in medical publications. Clin Pharmacol Ther. 1960 Jul-Aug;1:411-22. PMID: 14420026.
Copy Download .nbib Format: NLM
Clinical Pharmacology & Therapeutics annual report 2002.

Clinical pharmacology and therapeutics

Stein CM.
PMID: 12891219
Clin Pharmacol Ther. 2003 Aug;74(2):99-101. doi: 10.1016/S0009-9236(03)00149-8.

No abstract available.

Cite
Stein CM. Clinical Pharmacology & Therapeutics annual report 2002. Clin Pharmacol Ther. 2003;74(2):99-101doi: 10.1016/S0009-9236(03)00149-8.
Stein, C. M. (2003). Clinical Pharmacology & Therapeutics annual report 2002. Clinical pharmacology and therapeutics, 74(2), 99-101. https://doi.org/10.1016/S0009-9236(03)00149-8
Stein, C Michael. "Clinical Pharmacology & Therapeutics annual report 2002." Clinical pharmacology and therapeutics vol. 74,2 (2003): 99-101. doi: https://doi.org/10.1016/S0009-9236(03)00149-8
Stein CM. Clinical Pharmacology & Therapeutics annual report 2002. Clin Pharmacol Ther. 2003 Aug;74(2):99-101. doi: 10.1016/S0009-9236(03)00149-8. PMID: 12891219.
Copy Download .nbib Format: NLM
Academic medical centers and the pharmaceutical industry.

Clinical pharmacology and therapeutics

Del Parigi A.
PMID: 20703224
Clin Pharmacol Ther. 2010 Oct;88(4):464-5. doi: 10.1038/clpt.2010.162. Epub 2010 Aug 11.

No abstract available.

Cite
Del Parigi A. Academic medical centers and the pharmaceutical industry. Clin Pharmacol Ther. 2010;88(4):464-5doi: 10.1038/clpt.2010.162.
Del Parigi, A. (2010). Academic medical centers and the pharmaceutical industry. Clinical pharmacology and therapeutics, 88(4), 464-5. https://doi.org/10.1038/clpt.2010.162
Del Parigi, A. "Academic medical centers and the pharmaceutical industry." Clinical pharmacology and therapeutics vol. 88,4 (2010): 464-5. doi: https://doi.org/10.1038/clpt.2010.162
Del Parigi A. Academic medical centers and the pharmaceutical industry. Clin Pharmacol Ther. 2010 Oct;88(4):464-5. doi: 10.1038/clpt.2010.162. Epub 2010 Aug 11. PMID: 20703224.
Copy Download .nbib Format: NLM
When should re-consent of subjects participating in a clinical trial be requested? A case-oriented algorithm to assist in the decision-making process.

Clinical pharmacology and therapeutics

Dal-Ré R, Avendaño C, Gil-Aguado A, Gracia D, Caplan AL.
PMID: 17882160
Clin Pharmacol Ther. 2008 May;83(5):788-93. doi: 10.1038/sj.clpt.6100357. Epub 2007 Sep 19.

Investigators, sponsors, and institutional review boards have to decide when re-consent of clinical trials' participants must be obtained when new information becomes available. We present an algorithm to help in the decision-making process, which takes into consideration the kind...

Cite
Dal-Ré R, Avendaño C, Gil-Aguado A, et al. When should re-consent of subjects participating in a clinical trial be requested? A case-oriented algorithm to assist in the decision-making process. Clin Pharmacol Ther. 2007;83(5):788-93doi: 10.1038/sj.clpt.6100357.
Dal-Ré, R., Avendaño, C., Gil-Aguado, A., Gracia, D., & Caplan, A. L. (2008). When should re-consent of subjects participating in a clinical trial be requested? A case-oriented algorithm to assist in the decision-making process. Clinical pharmacology and therapeutics, 83(5), 788-93. https://doi.org/10.1038/sj.clpt.6100357
Dal-Ré, R, et al. "When should re-consent of subjects participating in a clinical trial be requested? A case-oriented algorithm to assist in the decision-making process." Clinical pharmacology and therapeutics vol. 83,5 (2008): 788-93. doi: https://doi.org/10.1038/sj.clpt.6100357
Dal-Ré R, Avendaño C, Gil-Aguado A, Gracia D, Caplan AL. When should re-consent of subjects participating in a clinical trial be requested? A case-oriented algorithm to assist in the decision-making process. Clin Pharmacol Ther. 2008 May;83(5):788-93. doi: 10.1038/sj.clpt.6100357. Epub 2007 Sep 19. PMID: 17882160.
Copy Download .nbib Format: NLM
A NOTE ON NAMES.

Clinical pharmacology and therapeutics

CUTTING W.
PMID: 14060196
Clin Pharmacol Ther. 1963 Sep-Oct;4:569-72. doi: 10.1002/cpt196345569.

No abstract available.

Cite
CUTTING W. A NOTE ON NAMES. Clin Pharmacol Ther. 1963;4:569-72doi: 10.1002/cpt196345569.
CUTTING, W. (1963). A NOTE ON NAMES. Clinical pharmacology and therapeutics, 4569-72. https://doi.org/10.1002/cpt196345569
CUTTING, W. "A NOTE ON NAMES." Clinical pharmacology and therapeutics vol. 4 (1963): 569-72. doi: https://doi.org/10.1002/cpt196345569
CUTTING W. A NOTE ON NAMES. Clin Pharmacol Ther. 1963 Sep-Oct;4:569-72. doi: 10.1002/cpt196345569. PMID: 14060196.
Copy Download .nbib Format: NLM
Managing the innovation supply chain to maximize personalized medicine.

Clinical pharmacology and therapeutics

Waldman SA, Terzic A.
PMID: 24448453
Clin Pharmacol Ther. 2014 Feb;95(2):113-8. doi: 10.1038/clpt.2013.228.

Personalized medicine epitomizes an evolving model of care tailored to the individual patient. This emerging paradigm harnesses radical technological advances to define each patient's molecular characteristics and decipher his or her unique pathophysiological processes. Translated into individualized algorithms, personalized...

Cite
Waldman SA, Terzic A. Managing the innovation supply chain to maximize personalized medicine. Clin Pharmacol Ther. 2014;95(2):113-8doi: 10.1038/clpt.2013.228.
Waldman, S. A., & Terzic, A. (2014). Managing the innovation supply chain to maximize personalized medicine. Clinical pharmacology and therapeutics, 95(2), 113-8. https://doi.org/10.1038/clpt.2013.228
Waldman, S A, and Terzic, A. "Managing the innovation supply chain to maximize personalized medicine." Clinical pharmacology and therapeutics vol. 95,2 (2014): 113-8. doi: https://doi.org/10.1038/clpt.2013.228
Waldman SA, Terzic A. Managing the innovation supply chain to maximize personalized medicine. Clin Pharmacol Ther. 2014 Feb;95(2):113-8. doi: 10.1038/clpt.2013.228. PMID: 24448453.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 520 entries